drugset / Trial / NCT00561275
Safety Study of Multiple Peptide Vaccine to Esophageal Cancer
Phase 1
Completed
6 enrolled
Japanese Foundation for Cancer Research
Human Genome Center, Institute of Medical Science, University of Tokyo · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1 study of multiple peptide vaccine therapy and GM-CSF in treating patients with esophageal cancer.
Timeline
- Start
- 2007-10
- Primary completion
- 2008-05
- Completion
- 2008-06
Publications
- Background Ishizaki H, Tsunoda T, Wada S, Yamauchi M, Shibuya M, Tahara H. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin Cancer Res. 2006 Oct 1;12(19):5841-9. doi: 10.1158/1078-0432.CCR-06-0750.
- Background Wada S, Tsunoda T, Baba T, Primus FJ, Kuwano H, Shibuya M, Tahara H. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 2005 Jun 1;65(11):4939-46. doi: 10.1158/0008-5472.CAN-04-3759.
- Background Suda T, Tsunoda T, Daigo Y, Nakamura Y, Tahara H. Identification of human leukocyte antigen-A24-restricted epitope peptides derived from gene products upregulated in lung and esophageal cancers as novel targets for immunotherapy. Cancer Sci. 2007 Nov;98(11):1803-8. doi: 10.1111/j.1349-7006.2007.00603.x.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LY6K | Unknown | — | — |
| Subject | VEGFR1 | Peptide | — | — |
| Subject | VEGFR2 | Peptide | — | — |
| Background | sargramostim | Protein / enzyme biologic | — | — |